Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1994 Dec;350(6):611-7.
doi: 10.1007/BF00169365.

Characterization of binding sites for [125I]R(+)trans-7-OH-PIPAT in rat brain

Affiliations

Characterization of binding sites for [125I]R(+)trans-7-OH-PIPAT in rat brain

M P Kung et al. Naunyn Schmiedebergs Arch Pharmacol. 1994 Dec.

Abstract

Binding characteristics of a novel radioiodinated ligand, [125I]R(+)trans-7-hydroxy-2-(N-n-propyl-N-3'-iodo-2'-propenyl) aminotetralin ([125I]R(+)trans-7-OH-PIPAT), were evaluated using homogenate binding and autoradiographic techniques in rat brain. [125I]R(+)trans-7-OH-PIPAT bound to sites (dopamine receptors) in homogenates of rat basal forebrain (including caudate putamen, nucleus accumbens and olfactory tubercle) with a high affinity (Kd = 0.42 nM). A majority (70%) of the sites labeled by [125I]R(+)trans-7-OH-PIPAT in basal forebrain were GTP-sensitive. In rat hippocampal homogenates, specific and saturable binding of [125I]R(+)trans-7-OH-PIPAT to 5-HT1A receptors, with a Kd value of 1.4 nM and a Bmax value of 210 fmol/mg protein, was observed. Binding of [125I]R(+)trans-7-OH-PIPAT to sigma sites was also demonstrated in rat cerebellar homogenates. In the presence of GTP (to inhibit binding to D2 and 5-HT1A receptors) and DTG (to inhibit binding to sigma sites), dopamine D3 receptors could be selectively labeled with [125I]R(+)trans-7-OH-PIPAT. [125I]R(+)trans-7-OH-PIPAT offers several unique advantages, including high specific activity and high affinity binding, which make it an excellent probe for the investigation and characterization of the distribution of dopamine D3 receptors.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Pharmacol Rev. 1990 Dec;42(4):355-402 - PubMed
    1. Annu Rev Pharmacol Toxicol. 1993;33:281-307 - PubMed
    1. FEBS Lett. 1991 May 6;282(2):441-4 - PubMed
    1. Int Rev Neurobiol. 1993;35:391-415 - PubMed
    1. Eur J Pharmacol. 1992 Aug 6;218(2-3):373-5 - PubMed

Publication types

Substances